Leaderna Biostructures
Leaderna Biostructures is a Warsaw-based structural biology CRO providing X-ray crystallography and cryo-EM services (Gene-to-Structure pipeline) to pharmaceutical and biotechnology companies for structure-based drug design, with specialization in protein-nucleic acid complexes and a risk-sharing, success-fee pricing model.
- Company typePrivate
- Founded2020
- HeadquartersWarsaw, Poland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Leaderna Biostructures does
Leaderna Biostructures Sp. z o.o. is a privately held Polish structural-biology contract research organization founded in 2020 by Pawel Kustosz and headquartered at the University of Warsaw's Biological and Chemical Research Centre (CNBCh UW) in Warsaw. The firm delivers high-resolution 3D structure determination services for pharmaceutical and biotechnology clients engaged in structure-based drug design, with a particular specialization in protein–nucleic acid complexes developed through cooperation with IONIS Pharmaceuticals.
The company's core offering is the "Gene-to-Structure" pipeline, an integrated workflow covering expression-construct design, recombinant protein production, crystallization and X-ray diffraction (including synchrotron measurements), single-particle cryo-EM on Glacios 200 kV and Titan Krios 300 kV microscopes, and biophysical/biochemical characterization of target-ligand interactions. A proprietary site-specific cross-linking technology enables stabilization of transient and unstable protein–DNA/RNA complexes that resist standard co-crystallization. Leaderna positions as the first commercial cryo-EM provider in Poland and is built around a small bench of domain experts (CEO Kustosz, CSO Agnieszka Napiórkowska, CFO Sylwester Pobiarzyn, BD Przemysław Putno), with deep ties to the International Institute of Molecular and Cell Biology in Warsaw and Polish science centers.
Commercially, Leaderna operates a B2B service model selling directly to pharmaceutical companies across Poland, the Netherlands, and the United States. Revenue is generated through project-based structure-determination engagements priced under a risk-sharing model (preliminary experiments at operational cost, with success-fee structuring upon satisfactory delivery), supplemented by an EU funds assistance service where Leaderna acts as co-contractor or subcontractor on grant-funded crystallography programs. The named customer base spans IONIS Pharmaceuticals, UbiQ Bio, Adamed Pharma, Celon Pharma, OncoArendi Therapeutics, and Selvita, with cumulative disclosed project outputs of 13 protein-inhibitor structures solved for OncoArendi (whose OATD-01 compound is in clinical trials for sarcoidosis) and four structures solved for Adamed.
Leaderna Biostructures firmographics
Firmographics- Name
- Leaderna Biostructures
- Legal name
- Leaderna Biostructures Sp. z o.o.
- Website
- https://leaderna.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Leaderna Biostructures is a Warsaw-based structural biology CRO providing X-ray crystallography and cryo-EM services (Gene-to-Structure pipeline) to pharmaceutical and biotechnology companies for structure-based drug design, with specialization in protein-nucleic acid complexes and a risk-sharing, success-fee pricing model.
- Ownership category
- akta.pro rank
Leaderna Biostructures industry classification
Industry- Product category
- Structural Biology Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Leaderna Biostructures is headquartered
LocationHeadquarters
- HQ city
- Warsaw
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Leaderna Biostructures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Structural Biology Services: Service-based revenue from X-ray crystallography and cryo-EM analysis, including protein production, crystallization, structure determination, and biophysical characterization. Projects start with feasibility assessment followed by preliminary experiments at operational cost (risk-sharing model), with final payment as success fee upon satisfactory delivery.
- EU Funded Project Services: Assistance in obtaining EU funds for crystallography-based drug discovery, where Leaderna serves as co-contractor or subcontractor.
Go-to-market motion2 records
Distribution channels1 record
Leaderna Biostructures product offering
Product offeringCore offering
Leaderna Biostructures delivers Gene-to-Structure structural biology services for pharmaceutical and biotechnology drug discovery, covering gene construct design, recombinant protein production, crystallization, X-ray diffraction, cryo-EM analysis, and biophysical/biochemical characterization of protein-ligand interactions. The company specializes in structure-based drug design, with particular expertise in protein-nucleic acid complexes developed through cooperation with Ionis Pharmaceuticals.
Product overview
Leaderna Biostructures offers a unified service platform called Gene-to-Structure that provides end-to-end structural biology solutions for drug discovery. The platform integrates multiple service modules: Preparation of Expression Constructs, Recombinant Protein Production, X-ray Crystallography, Single-Particle Cryo-EM, and Biophysical and Biochemical Assays. A proprietary Unique Cross-linking Technology enables analysis of challenging protein-nucleic acid complexes. The services support structure-based drug design, hit-to-lead optimization, and lead optimization, with emphasis on nucleic acid-based therapeutics. Leaderna also provides EU Funds Assistance as a supporting service for funding applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Gene-to-Structure Services Comprehensive end-to-end structural biology service covering gene construct design, recombinant protein expression and purification, crystallization, X-ray diffraction and cryo-EM data collection, structure determination and refinement, and biophysical and biochemical characterization of target-ligand interactions. Designed for pharmaceutical and biotechnology companies engaged in structure-based drug design, hit-to-lead optimization, and lead optimization.
- EU Funds Assistance Services Service that assists small and medium pharmaceutical companies in obtaining EU funding for crystallography-based new molecule discovery projects. Leaderna collaborates with technology transfer centers and serves as co-contractor or subcontractor in EU-funded projects, providing structural biology expertise within grant-funded drug discovery consortia.
Quantifiable outcome
- Minimizes screening of thousands or millions of chemicals for protein tailoring
- +2 more outcomes
Companies that use Leaderna Biostructures
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Leaderna Biostructures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Leaderna Biostructures partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- IONIS PharmaceuticalscoreStrategic collaboration for solving protein-nucleic acid drug structures and joint patent development. This partnership expanded Leaderna's expertise in structure determination of nucleic acid-based drugs with proteins, positioning the company as a specialist in RNA-targeted therapeutics structural analysis.
- UbiQ BiocoreCollaboration for solving protein-inhibitor structures and scientific cooperation using cryo-EM technology.
- Adamed PharmacorePartnership for solving protein-inhibitor structures. Four structures have been solved with results to be published.
- Celon PharmacoreCollaboration on protein production and biophysical characterization under the prestigious InnoNeuroPharm NCBR grant.
- OncoArendi TherapeuticscorePartnership for solving protein-inhibitor structures. 13 structures have been solved with results to be published. The OATD-01 compound from this collaboration is in clinical trials as a potential first-in-class sarcoidosis drug.
- SelvitaminorCooperation in structure-based drug design projects with leading pharmaceutical company in central Europe.
- Polish Science CenterscoreClose collaboration with renowned experts and distinguished scientists in structural biology from Polish science centers, enabling execution of challenging projects.
- International Institute of Molecular and Cell Biology in Warsaw (IIMCB)coreFounder Pawel Kustosz led the IIMCB Structure Biology Center from 2015-2020. The company operates from the University of Warsaw Biological and Chemical Research Centre, maintaining close ties with this research institution.
- Technology Transfer CentersminorCooperation with technology transfer centers to assist clients in obtaining EU funds for crystallography-based drug discovery projects.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Leaderna Biostructures competitors and assessment
Company assessmentDirect peers
- Proteros Biostructures: Germany-based structural biology CRO offering X-ray crystallography and cryo-EM services for structure-based drug design; closest direct competitor to Leaderna with similar end-to-end structural biology workflow and pharma/biotech customer base.
- Creative Biostructure: Structural biology services provider offering protein crystallization, X-ray crystallography, cryo-EM, and protein production — directly competing in the same commercial service category as Leaderna.
- SARomics Biostructures: Sweden-based CRO specializing in protein crystallography, cryo-EM, and biophysical characterization for drug discovery — directly comparable service offering and target customers to Leaderna.
Broad incumbents
- Evotec: Global drug discovery CRO with structural biology and protein sciences capabilities embedded within its integrated discovery platform — broad incumbent overlapping with Leaderna's structure-based drug design services.
- Sygnature Discovery: UK-based integrated drug discovery CRO with structural biology, biophysics, and medicinal chemistry services — competes with Leaderna for structural biology engagements within broader discovery programs.
- Charles River Laboratories: Large global CRO offering structural biology and drug discovery services as part of a much broader portfolio; competes with Leaderna for enterprise pharma structural biology budgets but at significantly greater scale.
- WuXi AppTec (STA Pharmaceutical): Large China-based discovery and development services organization with structural biology capabilities; competes in the structural biology services market and serves global pharma clients.
- HitGen / Vernalis: Drug discovery company with heritage in structure-based design (Vernalis) and integrated with HitGen's platform; offers structure-based design services comparable to Leaderna's niche.
Others
- University of Warsaw Biological and Chemical Research Centre (CNBCh UW): Host institution where Leaderna is physically located and which provides access to advanced cryo-EM and synchrotron-linked infrastructure; functions as both an enabler and a potential non-commercial alternative for academic clients.
Regional players
- Life Sciences Discovery (e.g., Concept Life Sciences / Domainex): UK-based discovery CROs with structural biology and protein science capabilities; comparable service offerings to Leaderna but operating in a different European geography.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Leaderna Biostructures social profiles
Digital presenceLeaderna Biostructures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Leaderna Biostructures leadership team
Management profileNumber of profiles
Profiles5 records
Leaderna Biostructures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Leaderna Biostructures M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Leaderna Biostructures
What does Leaderna Biostructures do?
Leaderna Biostructures delivers Gene-to-Structure structural biology services for pharmaceutical and biotechnology drug discovery, covering gene construct design, recombinant protein production, crystallization, X-ray diffraction, cryo-EM analysis, and biophysical/biochemical characterization of protein-ligand interactions. The company specializes in structure-based drug design, with particular expertise in protein-nucleic acid complexes developed through cooperation with Ionis Pharmaceuticals.
Is Leaderna Biostructures a public or private company?
Leaderna Biostructures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Leaderna Biostructures founded?
Leaderna Biostructures was founded in 2020. It employs 1 to 10 people.
Where is Leaderna Biostructures based?
Leaderna Biostructures is headquartered in Warsaw, Poland, in the Europe region.
How does Leaderna Biostructures make money?
Two revenue lines are on record. Structural Biology Services are the primary driver. The others are EU Funded Project Services.
Who are Leaderna Biostructures's main competitors?
Direct peers on record are Proteros Biostructures, Creative Biostructure and SARomics Biostructures. Broad incumbents are Evotec, Sygnature Discovery, Charles River Laboratories, WuXi AppTec (STA Pharmaceutical) and HitGen / Vernalis. University of Warsaw Biological and Chemical Research Centre (CNBCh UW) is listed as an others. Life Sciences Discovery (e.g., Concept Life Sciences / Domainex) is listed as a regional player.
Does Leaderna Biostructures have an API?
No public API is recorded for Leaderna Biostructures.
What industry is Leaderna Biostructures in?
Leaderna Biostructures's product category is Structural Biology Services. Its primary akta.pro industry code is HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 8731.